» Articles » PMID: 25625846

Overexpression of HOX Genes is Prevalent in Ewing Sarcoma and is Associated with Altered Epigenetic Regulation of Developmental Transcription Programs

Overview
Journal Epigenetics
Specialty Genetics
Date 2015 Jan 28
PMID 25625846
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The polycomb proteins BMI-1 and EZH2 are highly overexpressed by Ewing sarcoma (ES), a tumor of stem cell origin that is driven by EWS-ETS fusion oncogenes, most commonly EWS-FLI1. In the current study we analyzed expression of transcription programs that are controlled by polycomb proteins during embryonic development to determine if they are abnormal in ES. Our results show that polycomb target gene expression in ES deviates from normal tissues and stem cells and that, as expected, most targets are relatively repressed. However, we also discovered a paradoxical up regulation of numerous polycomb targets and these were highly enriched for homeobox (HOX) genes. Comparison of HOX profiles between malignant and non-malignant tissues revealed a distinctive HOX profile in ES, which was characterized by overexpression of posterior HOXD genes. In addition, ectopic expression of EWS-FLI1 during stem cell differentiation led to aberrant up regulation of posterior HOXD genes. Mechanistically, this up regulation was associated with altered epigenetic regulation. Specifically, ES and EWS-FLI1+ stem cells displayed a relative loss of polycomb-dependent H3K27me3 and gain of trithorax-dependent H3K4me3 at the promoters of posterior HOXD genes and also at the HOXD11.12 polycomb response element. In addition, a striking correlation was evident between HOXD13 and other genes whose regulation is coordinately regulated during embryonic development by distal enhancer elements. Together, these studies demonstrate that epigenetic regulation of polycomb target genes, in particular HOXD genes, is altered in ES and that these changes are mediated downstream of EWS-FLI1.

Citing Articles

Origin of Ewing sarcoma by embryonic reprogramming of neural crest to mesoderm.

Vasileva E, Arata C, Luo Y, Burgos R, Crump J, Amatruda J bioRxiv. 2024; .

PMID: 39554045 PMC: 11565755. DOI: 10.1101/2024.10.27.620438.


Menin in Cancer.

Majer A, Hua X, Katona B Genes (Basel). 2024; 15(9).

PMID: 39336822 PMC: 11431421. DOI: 10.3390/genes15091231.


Uterine Tumor Resembling Ovarian Sex-Cord Tumor (UTROSCT): A Rare Polyphenotypic Neoplasm.

Giordano G, Guareschi D, Thai E Diagnostics (Basel). 2024; 14(12).

PMID: 38928686 PMC: 11203005. DOI: 10.3390/diagnostics14121271.


EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.

Yasir M, Park J, Chun W Int J Mol Sci. 2023; 24(20).

PMID: 37894854 PMC: 10607184. DOI: 10.3390/ijms242015173.


Maintenance of neuronal identity in C. elegans and beyond: Lessons from transcription and chromatin factors.

Destain H, Prahlad M, Kratsios P Semin Cell Dev Biol. 2023; 154(Pt A):35-47.

PMID: 37438210 PMC: 10592372. DOI: 10.1016/j.semcdb.2023.07.001.


References
1.
Williamson I, Eskeland R, Lettice L, Hill A, Boyle S, Grimes G . Anterior-posterior differences in HoxD chromatin topology in limb development. Development. 2012; 139(17):3157-67. PMC: 3413162. DOI: 10.1242/dev.081174. View

2.
. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 2011; 9(4):e1001046. PMC: 3079585. DOI: 10.1371/journal.pbio.1001046. View

3.
Sparmann A, van Lohuizen M . Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-56. DOI: 10.1038/nrc1991. View

4.
Andrey G, Montavon T, Mascrez B, Gonzalez F, Noordermeer D, Leleu M . A switch between topological domains underlies HoxD genes collinearity in mouse limbs. Science. 2013; 340(6137):1234167. DOI: 10.1126/science.1234167. View

5.
Brohl A, Solomon D, Chang W, Wang J, Song Y, Sindiri S . The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014; 10(7):e1004475. PMC: 4091782. DOI: 10.1371/journal.pgen.1004475. View